0001527728 false 0001527728 2021-08-30 2021-08-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 30, 2021

 

ENOCHIAN BIOSCIENCES INC.
(Exact name of registrant as specified in its charter)

 

Delaware   000-54478   45-2559340
(State or other jurisdiction   (Commission File Number)   (I.R.S. Employer
of incorporation)       Identification No.)

 

    2080 Century City East  
Suite 906  
Los Angeles, CA 90067  
(Address of principal executive offices)

  

+1 (305) 918-1980

(Registrant’s telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol   Name of Each Exchange on Which Registered
Common Stock, par value $0.0001 per share   ENOB   The Nasdaq Stock Market LLC

`

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

 

Item 8.01. Other Events.

 

On August 30, 2021, Enochian Biosciences Inc. (the “Company”) issued a press release announcing the appointment of Dr. Peter Piot, KCMG, FRCP and Dr. Richard Whitley, MD to the Company’s Scientific Advisory Board. A copy of the press release is attached hereto as Exhibit 99.1, and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

  (d)  Exhibits

 

Exhibit No.   Description
     
99.1   Press Release dated August 30, 2021.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ENOCHIAN BIOSCIENCES, INC.
   
  By:  /s/ Luisa Puche
    Name: Luisa Puche
Title: Chief Financial Officer

 

Date: August 30, 2021

 

 

 

 

Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Enochian Biosciences Charts.
Enochian Biosciences (NASDAQ:ENOB)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Enochian Biosciences Charts.